Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01081262 · OUTCOME

Progression-free Survival

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer · Source last updated 2026-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Is measured from date of randomization until first indication of progression based on RECIST criteria or death from any cause, or if progression-free at last contact, the date of last disease assessment up to 10 years.

What was measured

Progression is defined using Response Evaluation Criteria in Solid Tumors criteria (RECIST v1.0) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Analysis population: All Randomized Patients

Groups in this outcome

Arm I (Carboplatin and Paclitaxel)

Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Carboplatin: Given IV Laboratory Biomarker Analysis: Correlative studies Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies

Arm II (Oxaliplatin and Capecitabine)

Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Capecitabine: Given PO Laboratory Biomarker Analysis: Correlative studies Oxaliplatin: Given IV Quality-of-Life Assessment: Ancillary studies

Arm III (Carboplatin, Paclitaxel, Bevacizumab)

Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Bevacizumab: Given IV Carboplatin: Given IV Laboratory Biomarker Analysis: Correlative studies Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies

Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)

Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III. Bevacizumab: Given IV Capecitabine: Given PO Laboratory Biomarker Analysis: Correlative studies Oxaliplatin: Given IV Quality-of-Life Assessment: Ancillary studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I (Carboplatin and Paclitaxel)13
Arm II (Oxaliplatin and Capecitabine)13
Arm III (Carboplatin, Paclitaxel, Bevacizumab)13
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)11

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm I (Carboplatin and Paclitaxel)36.1Not reported2.0NAUpper limit not yet reached
Arm II (Oxaliplatin and Capecitabine)7.4Not reported4.5NAUpper limit not yet reached
Arm III (Carboplatin, Paclitaxel, Bevacizumab)15.4Not reported4.9NAUpper limit not yet reached
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)23.3Not reported9.1NAUpper limit not yet reached
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Upper limit not yet reached
        group Id
        OG000
        lower Limit
        2.0
        upper Limit
        NA
        value
        36.1
      2. comment
        Upper limit not yet reached
        group Id
        OG001
        lower Limit
        4.5
        upper Limit
        NA
        value
        7.4
      3. comment
        Upper limit not yet reached
        group Id
        OG002
        lower Limit
        4.9
        upper Limit
        NA
        value
        15.4
      4. comment
        Upper limit not yet reached
        group Id
        OG003
        lower Limit
        9.1
        upper Limit
        NA
        value
        23.3
denoms
  1. counts
    1. group Id
      OG000
      value
      13
    2. group Id
      OG001
      value
      13
    3. group Id
      OG002
      value
      13
    4. group Id
      OG003
      value
      11
    units
    Participants
description
Progression is defined using Response Evaluation Criteria in Solid Tumors criteria (RECIST v1.0) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Carboplatin: Given IV Laboratory Biomarker Analysis: Correlative studies Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies
    id
    OG000
    title
    Arm I (Carboplatin and Paclitaxel)
  2. description
    Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Capecitabine: Given PO Laboratory Biomarker Analysis: Correlative studies Oxaliplatin: Given IV Quality-of-Life Assessment: Ancillary studies
    id
    OG001
    title
    Arm II (Oxaliplatin and Capecitabine)
  3. description
    Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Bevacizumab: Given IV Carboplatin: Given IV Laboratory Biomarker Analysis: Correlative studies Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies
    id
    OG002
    title
    Arm III (Carboplatin, Paclitaxel, Bevacizumab)
  4. description
    Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III. Bevacizumab: Given IV Capecitabine: Given PO Laboratory Biomarker Analysis: Correlative studies Oxaliplatin: Given IV Quality-of-Life Assessment: Ancillary studies
    id
    OG003
    title
    Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)
param Type
MEDIAN
population Description
All Randomized Patients
reporting Status
POSTED
time Frame
Is measured from date of randomization until first indication of progression based on RECIST criteria or death from any cause, or if progression-free at last contact, the date of last disease assessment up to 10 years.
title
Progression-free Survival
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice